Sep 2, 2024

InvAscent has successfully exited its investment in Inventia, with a sale of its stake to Platinum Equity, a global investment firm specializing in the acquisition and operation of companies.

InvAscent invested in Inventia in 2020, recognizing the company’s potential in formulations and innovative drug delivery systems. The investment enabled Inventia to strengthen its operations, expand its market reach, and enhance its R&D capabilities. Over the years, Inventia has grown substantially, establishing itself as a key player in the industry with a robust portfolio of products and a strong presence in developed as well as emerging pharma markets.

Currently, Inventia serves as a partner to over 100 customers supplying semi-finished and finished OSD formulations for both regular and value-added generics across North America, South America, Europe, Southeast Asia, Middle East and Africa.

The sale to Platinum Equity marks a significant milestone for Inventia, providing the company with new opportunities to accelerate its growth and innovation agenda.

 About InvAscent

Founded in 2005, InvAscent is the investment advisor to a family of funds that operate under the name “India Life Sciences Fund” or ILSF. It has so far raised about USD 650 Mn from global investors across four funds and deployed the same in 36 companies across Pharma, Healthcare Delivery, HealthTech, Medical Devices, and Animal Health industries. The investment team at InvAscent has deep domain expertise and a track record of value creation in the Life Sciences space.

For more information about InvAscent, please visit www.invascent.com